Research programme: plasma derived therapeutics - ProThera Biologics/Takeda
Latest Information Update: 28 May 2024
At a glance
- Originator ProThera Biologics
- Developer ProThera Biologics; Takeda
- Class Anti-inflammatories; Proteins
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation